PROSTATE HEALTH INDEX (PHI)
Prostate health index (PHI) combines three PSA forms (total PSA, free PSA, and p2PSA) into a single score. p2PSA test measures the proPSA concentration in serum. ProPSA is one of the isoform of free PSA which has been determined to be most specific to Prostate cancer. PHI demonstrates a significant improvement in clinical specificity for prostate cancer detection, relative to PSA alone in men 50 years of age or older with a PSA range of 2-10 ng/mL and with non-suspicious digital rectal exam (DRE) findings. At 95% clinical sensitivity, the clinical specificity for PHI is 18.2% as compared to 6.6% for free PSA in diagnostic grey zone. A low PHI result indicates lower risk of Prostate cancer, while an elevated PHI result may suggest that a prostate biopsy is necessary to rule out cancer.
Parameter(s) covered : 5
Report Frequency: Sample Mon / Thu by 11 am; Report Same day
Special Instruction: Do not give sample within 7 days of Digital Rectal Examination (DRE) or Rectal Prostatic Ultrasonography.
Price : ₹ 3000.00
Parameters
- PSA (PROSTATE SPECIFIC ANTIGEN), TOTAL, SERUM
- PSA, FREE
- p2PSA
- PHI
- Free / Total PSA Ratio